<p>Avoro Capital Advisors LLC 在第四季度根据最新提交给证券交易委员会的 13F 申报文件，将其持有的 Taysha Gene Therapies, Inc.（纳斯达克股票代码：TSHA）股份增加了 11.0%。该公司在该时期购买了额外的 430,555 股，持有公司股票的股份数为 4,355,555 股。根据最新的 SEC 申报，Avoro Capital Advisors LLC 持有 Taysha Gene Therapies 约价值$7,709,000 的股份。</p>
<p>获取 <strong>Taysha Gene Therapies</strong> 警报：</p>
<ul>
<li>3 家小市值股票，适合您的秋季购物清单</li>
</ul>
<p>其他几家机构投资者和对冲基金也调整了他们对 TSHA 的持股。花旗集团在第三季度收购了 Taysha Gene Therapies 的新股份，价值$888,000。FMR LLC 在第三季度增加了其对 Taysha Gene Therapies 的持股，增幅达到 2,035.0%。FMR LLC 现在拥有公司股票的 24,527,801 股，价值$77,508,000，较上一季度增加了 23,378,974 股。EAM Investors LLC 在第三季度收购了 Taysha Gene Therapies 的新头寸，价值$1,060,000。Acuta Capital Partners LLC 在第三季度购买了 Taysha Gene Therapies 的新头寸，价值约$12,096,000。最后，Vanguard Group Inc.在第三季度将其对 Taysha Gene Therapies 的持股增加了 235.2%。Vanguard Group Inc.现在拥有公司股票的 5,327,864 股，价值$16,836,000，较上一季度增加了 3,738,616 股。目前，77.70% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>Taysha Gene Therapies 股价表现</h2>
<p>Taysha Gene Therapies 股票在周一的午盘交易中下跌了$0.03，报$3.92。该公司的交易量为 1,005,530 股，相比其平均交易量 2,383,907 股有所下降。该公司的流动比率为 3.38，速动比率为 3.38，负债权益比为 0.75。该公司的市值为$7.3312 亿，市盈率为-8.00，贝塔系数为 0.49。该股的五十天简单移动平均线为$2.85，二百天简单移动平均线为$2.28。Taysha Gene Therapies, Inc.的一年最低价为$0.50，最高价为$4.02。</p>
<p>Taysha Gene Therapies（纳斯达克股票代码：TSHA）最近发布了其季度财报，报告显示，截至 5 月 14 日的周二，公司每股亏损为 ($0.10)，超过了分析师预期的 ($0.11)。Taysha Gene Therapies 的净利润率为-833.60%，净资产收益率为-782.81%。该季度，公司营收为$3.41 百万，略低于分析师预期的$3.70 百万。去年同期，公司每股亏损为 ($0.28)。作为一个整体，股票研究分析师预测，Taysha Gene Therapies, Inc.今年将实现每股-0.43 的亏损。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究分析师最近对 TSHA 发表了评论。Piper Sandler 在 4 月 9 日的研究报告中对 Taysha Gene Therapies 进行了覆盖。他们给予公司 “超配” 评级，并为该公司设定了$9.00 的目标股价。Needham &amp; Company LLC 在 5 月 15 日的研究报告中重申了对 Taysha Gene Therapies 的 “买入” 评级，并设定了$7.00 的股价目标。Cantor Fitzgerald 在 5 月 28 日的研究报告中重申了对 Taysha Gene Therapies 的 “超配” 评级，并设定了$7.00 的股价目标。Chardan Capital 将 Taysha Gene Therapies 的股价目标从$5.00 上调至$7.00，并给予该股 “买入” 评级。最后，JMP Securities 重申了对 Taysha Gene Therapies 的 “市场跑赢” 评级，并在 3 月 20 日的研究报告中设定了$5.00 的目标股价。根据 MarketBeat.com 的数据，共有九位研究分析师对该股票给予买入评级。Taysha Gene Therapies 目前的共识评级为 “买入”，共识目标股价为$7.00。</p>
<p><strong>阅读我们关于 TSHA 的最新研究报告</strong></p>
<h2>Taysha Gene Therapies 简介（免费报告）</h2>
<p>Taysha Gene Therapies, Inc.是一家基因疗法公司，专注于开发和商业化基于腺相关病毒的基因疗法，用于治疗中枢神经系统的单基因疾病。其主要开发项目包括用于治疗巨大轴突神经病的 TSHA-120；用于治疗雷特综合征的 TSHA-102；用于治疗 CLN7 病的 TSHA-121；用于治疗 CLN1 病的 TSHA-118；用于治疗 SLC13A5 缺乏症的 TSHA-105；用于治疗 tau 蛋白病的 TSHA-113；用于治疗安吉曼综合征的 TSHA-106；用于治疗脆性 X 综合征的 TSHA-114；以及用于治疗 GM2 神经节苷脂病的 TSHA-101。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票，比 Taysha Gene Therapies 更好</li>
<li>投资高市盈率增长股</li>
<li>我们的全面风险承受能力评估</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>Autodesk 在完成审计调查后提高了业绩指引</li>
<li>如何阅读股票图表，适合初学者</li>
<li>Lyft 股票在投资者日发布大胆的 2027 年业绩指引后出现跳空和垃圾股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 是时候摆脱中国的锂了！（来自 Smallcaps Daily）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw"/></p>
<h2>您现在是否应该投资$1,000 购买 Taysha Gene Therapies？</h2>
<p>在考虑购买 Taysha Gene Therapies 之前，您需要听听这个建议。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场的关注... 而 Taysha Gene Therapies 并不在这份名单上。</p>
<p>尽管 Taysha Gene Therapies 目前在分析师中有一个&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TSHA

<p>Avoro Capital Advisors LLC 根据最近向证券交易委员会提交的文件，在第四季度增加了对 Taysha Gene Therapies 的持股比例，增幅为 11%。Avoro Capital Advisors 现在拥有该公司 435 万 5555 股的股份，价值 770 万美元。其他机构投资者和对冲基金也调整了他们对 TSHA 的持股。Taysha Gene Therapies 是一家专注于开发中枢神经系统单基因疾病治疗的基因治疗公司</p>

<p>Avoro Capital Advisors LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.0% in the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 4,355,555 shares of the company's stock after buying an additional 430,555 shares during the period. Avoro Capital Advisors LLC owned about 2.33% of Taysha Gene Therapies worth $7,709,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Avoro Capital Advisors LLC 在第四季度根据最新提交给证券交易委员会的 13F 申报文件，将其持有的 Taysha Gene Therapies, Inc.（纳斯达克股票代码：TSHA）股份增加了 11.0%。该公司在该时期购买了额外的 430,555 股，持有公司股票的股份数为 4,355,555 股。根据最新的 SEC 申报，Avoro Capital Advisors LLC 持有 Taysha Gene Therapies 约价值$7,709,000 的股份。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Taysha Gene Therapies</strong> 警报：</p>
<ul>
<li>3 家小市值股票，适合您的秋季购物清单</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also modified their holdings of TSHA. Citigroup Inc. acquired a new stake in Taysha Gene Therapies during the third quarter valued at $888,000. FMR LLC raised its holdings in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company's stock valued at $77,508,000 after purchasing an additional 23,378,974 shares in the last quarter. EAM Investors LLC acquired a new position in Taysha Gene Therapies during the third quarter worth $1,060,000. Acuta Capital Partners LLC bought a new position in Taysha Gene Therapies during the third quarter valued at about $12,096,000. Finally, Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company's stock worth $16,836,000 after purchasing an additional 3,738,616 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也调整了他们对 TSHA 的持股。花旗集团在第三季度收购了 Taysha Gene Therapies 的新股份，价值$888,000。FMR LLC 在第三季度增加了其对 Taysha Gene Therapies 的持股，增幅达到 2,035.0%。FMR LLC 现在拥有公司股票的 24,527,801 股，价值$77,508,000，较上一季度增加了 23,378,974 股。EAM Investors LLC 在第三季度收购了 Taysha Gene Therapies 的新头寸，价值$1,060,000。Acuta Capital Partners LLC 在第三季度购买了 Taysha Gene Therapies 的新头寸，价值约$12,096,000。最后，Vanguard Group Inc.在第三季度将其对 Taysha Gene Therapies 的持股增加了 235.2%。Vanguard Group Inc.现在拥有公司股票的 5,327,864 股，价值$16,836,000，较上一季度增加了 3,738,616 股。目前，77.70% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Taysha Gene Therapies Price Performance</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股价表现</h2>
</div><p>Shares of Taysha Gene Therapies stock traded down $0.03 during midday trading on Monday, reaching $3.92. The company had a trading volume of 1,005,530 shares, compared to its average volume of 2,383,907. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $733.12 million, a price-to-earnings ratio of -8.00 and a beta of 0.49. The stock has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $2.28. Taysha Gene Therapies, Inc. has a 1-year low of $0.50 and a 1-year high of $4.02.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 股票在周一的午盘交易中下跌了$0.03，报$3.92。该公司的交易量为 1,005,530 股，相比其平均交易量 2,383,907 股有所下降。该公司的流动比率为 3.38，速动比率为 3.38，负债权益比为 0.75。该公司的市值为$7.3312 亿，市盈率为-8.00，贝塔系数为 0.49。该股的五十天简单移动平均线为$2.85，二百天简单移动平均线为$2.28。Taysha Gene Therapies, Inc.的一年最低价为$0.50，最高价为$4.02。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The business had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same quarter last year, the business posted ($0.28) earnings per share. As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（纳斯达克股票代码：TSHA）最近发布了其季度财报，报告显示，截至 5 月 14 日的周二，公司每股亏损为 ($0.10)，超过了分析师预期的 ($0.11)。Taysha Gene Therapies 的净利润率为-833.60%，净资产收益率为-782.81%。该季度，公司营收为$3.41 百万，略低于分析师预期的$3.70 百万。去年同期，公司每股亏损为 ($0.28)。作为一个整体，股票研究分析师预测，Taysha Gene Therapies, Inc.今年将实现每股-0.43 的亏损。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research analysts recently commented on TSHA shares. Piper Sandler initiated coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an &#34;overweight&#34; rating and a $9.00 target price for the company. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, May 15th. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, May 28th. Chardan Capital raised their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 21st. Finally, JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $7.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对 TSHA 发表了评论。Piper Sandler 在 4 月 9 日的研究报告中对 Taysha Gene Therapies 进行了覆盖。他们给予公司 “超配” 评级，并为该公司设定了$9.00 的目标股价。Needham &amp; Company LLC 在 5 月 15 日的研究报告中重申了对 Taysha Gene Therapies 的 “买入” 评级，并设定了$7.00 的股价目标。Cantor Fitzgerald 在 5 月 28 日的研究报告中重申了对 Taysha Gene Therapies 的 “超配” 评级，并设定了$7.00 的股价目标。Chardan Capital 将 Taysha Gene Therapies 的股价目标从$5.00 上调至$7.00，并给予该股 “买入” 评级。最后，JMP Securities 重申了对 Taysha Gene Therapies 的 “市场跑赢” 评级，并在 3 月 20 日的研究报告中设定了$5.00 的目标股价。根据 MarketBeat.com 的数据，共有九位研究分析师对该股票给予买入评级。Taysha Gene Therapies 目前的共识评级为 “买入”，共识目标股价为$7.00。</p>
</div><p><strong>Read Our Latest Research Report on TSHA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TSHA 的最新研究报告</strong></p>
</div><h2>Taysha Gene Therapies Profile (Free Report)</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 简介（免费报告）</h2>
</div><p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc.是一家基因疗法公司，专注于开发和商业化基于腺相关病毒的基因疗法，用于治疗中枢神经系统的单基因疾病。其主要开发项目包括用于治疗巨大轴突神经病的 TSHA-120；用于治疗雷特综合征的 TSHA-102；用于治疗 CLN7 病的 TSHA-121；用于治疗 CLN1 病的 TSHA-118；用于治疗 SLC13A5 缺乏症的 TSHA-105；用于治疗 tau 蛋白病的 TSHA-113；用于治疗安吉曼综合征的 TSHA-106；用于治疗脆性 X 综合征的 TSHA-114；以及用于治疗 GM2 神经节苷脂病的 TSHA-101。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Our Comprehensive Risk Tolerance Assessment</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Autodesk Raises Guidance After Clearing Audit Investigation</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Lyft Stock Gap and Craps on Bold 2027 Guidance at Investor Day</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票，比 Taysha Gene Therapies 更好</li>
<li>投资高市盈率增长股</li>
<li>我们的全面风险承受能力评估</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>Autodesk 在完成审计调查后提高了业绩指引</li>
<li>如何阅读股票图表，适合初学者</li>
<li>Lyft 股票在投资者日发布大胆的 2027 年业绩指引后出现跳空和垃圾股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ It's time to ween off Chinese lithium! (From Smallcaps Daily)(Ad)</p>
<div class="lb-trans"><p>→ 是时候摆脱中国的锂了！（来自 Smallcaps Daily）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8280&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Taysha Gene Therapies right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 购买 Taysha Gene Therapies？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Taysha Gene Therapies 之前，您需要听听这个建议。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场的关注... 而 Taysha Gene Therapies 并不在这份名单上。</p>
</div><p>While Taysha Gene Therapies currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Taysha Gene Therapies 目前在分析师中有一个&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Avoro Capital Advisors LLC 在 Taysha Gene Therapies, Inc.（纳斯达克股票代码：TSHA）持有价值 771 万美元的股票头寸